The School of Medicine will use the SOPHiA
DDM™ Platform to expand its hematologic testing program for blood
cancers
BOSTON and ROLLE, Switzerland, Aug. 8, 2023
/PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a
cloud-native software company and a leader in data-driven
medicine, today announced that the Tulane
University School of Medicine in New Orleans, Louisiana is live on SOPHiA
GENETICS technology. The 15th oldest medical school in
the United States, Tulane University School of Medicine has a
longstanding history of medical research and education and will
leverage the SOPHiA DDM™ Platform to help scale its hematologic
(blood) testing program to advance blood cancer research.
Blood cancers account for nearly 10 percent of new cancer cases
in the U.S. each year1. While there are three main types
of blood cancer – leukemia, lymphoma, and myeloma – there are
over 100 different blood cancers that are now
recognized2. To help identify key biomarkers and aid in
stratification, labs are relying on next-generation sequencing
(NGS), which can produce a vast dataset. The SOPHiA DDM™ Platform
will enable the Tulane University
School of Medicine to quickly sort and analyze NGS data so that
researchers can share data-based recommendations with clinical
researchers, which is important as these malignancies can be
fast-moving.
"When the time came to upgrade our sequencing platform, the
SOPHiA DDM™ Platform provided a comprehensive heme panel sequencing
solution. SOPHiA GENETICS offered a chance to rapidly introduce the
new solutions to our service menu, and I am hopeful that this
integration of SOPHiA GENETICS technology to our workflow will be
the new start of our continuous efforts to improve the academic
center-based genetic/genomic diagnostic services from our
Louisiana communities to many more
areas." said Yuwen Li, MD, PhD,
Director of Molecular Genetics Diagnostic Laboratory , Tulane University School of Medicine.
The SOPHiA DDM™ Platform will also enable Tulane University School of Medicine to retain
custody of its samples and data. Each test performed can be stored
in the SOPHiA DDM™ Platform, which is a cloud-based platform
powered by Artificial Intelligence (AI) with patented technologies.
Having the ability to synthesize NGS data in-house will help
Tulane University School of Medicine
build its expertise and facilitate faster data turnaround from
researcher to clinical researcher, helping to positively impact
disease assessment.
"At SOPHiA GENETICS we believe in the power of data-driven
medicine and its ability to change the face of healthcare," said
Ken Freedman, Chief Revenue Officer,
SOPHiA GENETICS. "With the adoption
of the SOPHiA GENETICS Platform, we are confident that Tulane University School of Medicine will be able
to scale its program, further research of blood cancers, and
efficiently increase the use of precision medicine."
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.com or connect
on Twitter, LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
1 https://www.lls.org/facts-and-statistics/facts-and-statistics-overview
2 https://www.yalemedicine.org/conditions/blood-cancers#:~:text=%E2%80%9CWith%20over%20100%20different%20types,Huntington.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tulane-university-school-of-medicine-uses-sophia-genetics-to-advance-research-of-blood-cancers-301895094.html
SOURCE SOPHiA GENETICS